Consequences of irrational use of azithromycin during the COVID-19 pandemic
DOI:
https://doi.org/10.33448/rsd-v11i16.38771Keywords:
Azithromycin; Self-medication; COVID-19; Bacterial Pharmacoresistance.Abstract
Currently, the new virus called SARS-CoV-2, which causes the disease COVID-19, has caused a pandemic. Self-medication by the population was influenced by the media, through fake news and debates without scientific basis. The most used antibiotic was azithromycin, which is a drug from the macrolide group. The aim of this article is to describe and evaluate the consequences of the irrational use of the antibiotic Azithromycin during the COVID-19 pandemic. This is a systematic review that was carried out according to the recommendations of the PRISMA method. A bibliographical survey of indexed productions was carried out in the following electronic databases Scientific Electronic Library Online (SCIELO), in PubMed and VHL from January 2020 to June 2022. 10 articles were selected for this systematic review, the articles were analyzed and interpreted, with that, studies reported that most patients who were undergoing treatment for COVID-19 with Azithromycin or association with another drug did not have a significant improvement, in one study a combination of azithromycin with hydroxychloroquine proved to be more efficient for reduce viral load. The irrational use of this drug, in addition to increasing the incidence of adverse drug reactions, can contribute significantly to the increase in microbial resistance, requiring information and health education measures for physicians, other health professionals and users, in order to avoid the use and inappropriate prescription of these drugs.
References
Acevedo, K. C., Pinzón, C., Barrera, A., Padilla, E. L., & González, N. Y. (2020). Efficacy and safety of chloroquine, hydroxychloroquine and azithromycin in patients with COVID-19: Summary of evidence. Revista Colombiana De Nefrología, 7(Supl.2). https://revistanefrologia.org/index.php/rcn/article/view/469
Assis, D. H. E. (2021). CIÊNCIA X FAKE NEWS: o que há por trás da covid-19. Trabalho de Conclusão de Curso em Ciências Biológicas, Faculdade AGES, 2021. https://repositorio.animaeducacao.com.br/handle/ANIMA/19372
Brasil (2020). Ministério da Saúde. Orientações do Ministério da Saúde para Manuseio Medicamentoso Precoce de Pacientes com Diagnóstico da COVID-19. Brasília: Ministério da Saúde.
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C., Veiga, V. C., Avezum, A., ... & Berwanger, O. (2020). Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine, 383(21), 2041-2052. https://www.nejm.org/doi/full/10.1056/NEJMoa2019014
Carvalho, W., & Guimarães, Á. S. (2020). Desinformação, Negacionismo e Automedicação: a relação da população com as drogas “milagrosas” em meio à pandemia da COVID-19. InterAmerican Journal of Medicine and Health, 3. https://iajmh.emnuvens.com.br/iajmh/article/download/147/188
Coppi, M., Fialho, I., & Cid, M. (2021). Avaliação da literacia científica: revisão sistemática de literatura. Livro de Atas do Seminário. Évora: Universidade de Évora.
Dedic, V., Sljivo, A., Arnautovic, A., & Mulac, A. (2022). COVID-19 Vaccination Outcomes and Antibiotic Crisis and Overuse During the COVID-19 Pandemic in Bosnia and Herzegovina. Materia Socio-Medica, 34(2), 112. https://www.scienceopen.com/document_file/ea0be406-1a1c-4704-ab6e-9a5f0d0a73ac/PubMedCentral/ea0be406-1a1c-4704-ab6e-9a5f0d0a73ac.pdf
de Moura, J. M., Silva, L. M., de Souza, R. F., & Ramos, D. V. B. (2021). Indicação e uso de azitromicina no tratamento do COVID-19: revisão da literatura. Brazilian Journal of Development, 7(6), 56547-56556. https://scholar.archive.org/work/vqi3wv3dz5fdjptejh44xoqdpi/access/wayback/https://www. brazilianjournals.com/index.php/BRJD/article/download/31028/pdf
Del Fiol, F. D. S., Bergamaschi, C. D. C., De Andrade Jr, I. P., Lopes, L. C., Silva, M. T., & Barberato-Filho, S. (2022). Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic. Frontiers in Pharmacology, 13, 844818. https://www.frontiersin.org/articles/10.3389/fphar.2022.844818/pdf
Freires, M. S., & Junior, O. M. R. (2022). Resistência bacteriana pelo uso indiscriminado da azitromicina frente a Covid-19: uma revisão integrativa. Research, Society and Development, 11(1), e31611125035-e31611125035. https://rsdjournal.org/index.php/rsd/article/view/25035
Gautret, P., Lagier, J. C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., ... & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 56(1), 105949. https://www.sciencedirect.com/science/article/pii/S0924857920300996
Gerberding, J. L. (2020). Antibiotic resistance: the hidden threat lurking behind Covid-19. STAT. https://www.statnews.com/2020/03/23/antibiotic-resistance-hidden-threat-lurking-behind-covid-19/
Hentschke-Lopes, M., Botton, M. R., Borges, P., Freitas, M., Mancuso, A. C. B., & Matte, U. (2022). Sales of “COVID kit” drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency. Cadernos de Saúde Pública, 38, e00001022. https://www.scielosp.org/article/csp/2022.v38n7/e00001022/en/
Hinks, T. S., Cureton, L., Knight, R., Wang, A., Cane, J. L., Barber, V. S., ... & Richards, D. (2021). Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. The Lancet Respiratory Medicine, 9(10), 1130-1140. https://www.sciencedirect.com/science/article/pii/S2213260021002630
Lamback, E. B., Oliveira, M. A. D., Haddad, A. F., Vieira, A. F. M., Neto, A. L. F., Maia, T. D. S., ... & Costa, E. (2021). Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. Brazilian Journal of Infectious Diseases, 25. https://www.scielo.br/j/bjid/a/Dj6DgrhtkRCgvPDd7SqLydj/?lang=en&format=html
Lana, R. M., Coelho, F. C., Gomes, M. F. D. C., Cruz, O. G., Bastos, L. S., Villela, D. A. M., & Codeço, C. T. (2020). Emergência do novo coronavírus (SARS-CoV-2) e o papel de uma vigilância nacional em saúde oportuna e efetiva. Cadernos de Saúde Pública, 36. https://www.scielo.br/j/csp/a/sHYgrSsxqKTZNK6rJVpRxQL/
Melo, J. R. R., Duarte, E. C., Moraes, M. V. D., Fleck, K., Silva, A. S. D. N. E., & Arrais, P. S. D. (2021). Reações adversas a medicamentos em pacientes com COVID-19 no Brasil: análise das notificações espontâneas do sistema de farmacovigilância brasileiro. Cadernos de Saúde Pública, 37(1), e00245820. https://www.scielosp.org/pdf/csp/v37n1/1678-4464-csp-37-01-e00245820.pdf
Monge, K. M. M. (2013). Carbapenémicos: tipos y mecanismos de resistencia bacterianos. Revista médica de Costa Rica y centroamérica, 70(608), 599-605. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=47783
Navarrete-Mejía, P. J., Velasco-Guerrero, J. C., & Loro-Chero, L. (2020). Automedicación en época de pandemia: Covid-19. Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo, 13(4), 350-355. http://www.scielo.org.pe/scielo.php?pid=S2227-47312020000400350&script=sci_abstract&tlng=en
Nino-Orrego, M. J., Baracaldo-Santamaría, D., Patricia Ortiz, C., Zuluaga, H. P., Cruz-Becerra, S. A., Soler, F., ... & Calderon-Ospina, C. A. (2022). Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: a cross-sectional study. Therapeutic Advances in Drug Safety, 13, 20420986221101964. https://journals.sagepub.com/doi/abs/10.1177/20420986221101964
Oliveira, W. K., Duarte, E., França, G. V. A., & Garcia, L. P. (2020). Como o Brasil pode deter a COVID-19. Epidemiologia e Serviços de Saúde, 29(2). https://www.scielosp.org/pdf/ress/2020.v29n2/e2020044/
Orjuela-Rodríguez, T., Rojas-Cortés, R., Vergara, V., Aldunate, F., Jiménez, G., Orta, I. A., ... & Castro, J. L. (2022). Reacciones adversas a medicamentos utilizados para la COVID-19 en cinco países de América Latina. Rev Panam Salud Publica; 46, sept. 2022. https://iris.paho.org/handle/10665.2/56484
Paula, H. S. C., Santiago, S. B., Araújo, L. A., Pedroso, C. F., Marinho, T. A., Goncalves, I. A. J., ... & Batista, K. A. (2021). An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic. Brazilian Journal of Medical and Biological Research, 55. https://www.scielo.br/j/bjmbr/a/F7nLJzptrw8XNKgPkNkT8cy/abstract/?lang=en
Rawson, T. M., Moore, L. S., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., ... & Holmes, A. (2020). Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clinical infectious diseases, 71(9), 2459-2468. https://academic.oup.com/cid/article-abstract/71/9/2459/5828058
Vanzeler, M. L. (2021). A. Utilização De Azitromicina Para O Tratamento Da Covid-19: Uma Visão Crítica. Revista Científica Multidisciplinar Núcleo do Conhecimento. Ano, 6, 05-21. https://www.nucleodoconhecimento.com.br/saude/utilizacao-de-azitromicina
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., ... & Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. https://www.nejm.org/doi/full/10.1056/nejmoa2001017
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Alessandro Lopes de Almeida; Anna Clícia Lopes da Silva Araújo; Gleyce Kellen Monteiro da Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
